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Abstract
Background
Lymphatic filariasis (LF) and human immunodeficiency virus (HIV) are major public health
problems. Individuals may be co-infected, raising the possibility of important interactions be-
tween these two pathogens with consequences for LF elimination through annual mass
drug administration (MDA).
Methodology and Principal Findings
We analysed circulating filarial antigenaemia (CFA) by HIV infection status among adults in
two sites in northern Malawi, a region endemic for both LF and HIV. Stored blood samples
and data from two geographically separate studies were used: one a recruitment phase of a
clinical trial of anti-filarial agent dosing regimens, and the other a whole population annual
HIV sero-survey. In study one, 1,851 consecutive adult volunteers were screened for HIV
and LF infection. CFA prevalence was 25.4% (43/169) in HIV-positive and 23.6% (351/
1487) in HIV-negative participants (p=0.57). Geometric mean CFA concentrations were
859 and 1660 antigen units per ml of blood (Ag/ml) respectively, geometric mean ratio
(GMR) 0.85, 95%CI 0.49-1.50. In 7,863 adults in study two, CFA prevalence was 20.9%
(86/411) in HIV-positive and 24.0% (1789/7452) in HIV–negative participants (p=0.15).
Geometric mean CFA concentrations were 630 and 839 Ag/ml respectively (GMR 0.75,
95%CI 0.60-0.94). In the HIV-positive group, antiretroviral therapy (ART) use was associat-
ed with a lower CFA prevalence, 12.7% (18/142) vs. 25.3% (67/265), (OR 0.43, 95%CI
0.24-0.76). Prevalence of CFA decreased with duration of ART use, 15.2% 0-1 year (n=59),
13.6% >1-2 years (n=44), 10.0% >2-3 years (n=30) and 0% >3-4 years treatment (n=9),
p<0.01 χ2 for linear trend.
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Conclusions/Significance
In this large cross-sectional study of two distinct LF-exposed populations, there is no evi-
dence that HIV infection has an impact on LF epidemiology that will interfere with LF control
measures. A significant association of ART use with lower CFA prevalence merits further in-
vestigation to understand this apparent beneficial impact of ART.
Author Summary
Lymphatic filariasis (LF) and HIV are both major public health problems worldwide and
where they co-exist have the potential to interact. The main strategy for LF elimination is
annual mass drug administration (MDA). A particular concern is whether HIV, through
its impact on the immune system, will interfere with the effectiveness of this approach to
control and eliminate LF. We report findings from cross-sectional studies in two separate
populations in northern Malawi where both HIV and LF are common. One group (1,851
individuals) were studied at enrolment into a trial of anti-LF treatments, whilst the other
study used samples stored from adult participants in a whole population HIV survey
(7,863 individuals). Between 5–10% of the study participants were HIV-positive and 24%
were LF-infected. We found no evidence that LF infection was more or less common in
HIV-positive adults in either population. However, we identified robust evidence that an-
tiretroviral therapy use was associated with lower LF prevalence rates. We have no evi-
dence to suggest HIV will have a detrimental effect on LF control. On the contrary, the
evidence suggests that antiretroviral therapy may have beneficial effects and merits further
careful evaluation of the anti-filarial properties of these compounds.
Introduction
Human immunodeficiency virus (HIV) and parasitic infections affect widely overlapping pop-
ulations in sub-Saharan Africa. Of the estimated 35 million people infected with HIV world-
wide at the end of 2013, about 70% were from sub-Saharan Africa [1]. Parasitic infections,
including lymphatic filariasis (LF) are also widespread in sub-Saharan Africa, raising the possi-
bility of clinically significant interactions between the two pathogens. It has been suggested
that HIV and parasitic co-infections may have bidirectional deleterious interactions by affect-
ing susceptibility to HIV, impacting on HIV progression and potentially worsening clinical
outcomes of filarial infection [2]. Previous in-vitro studies have shown helminth infections to
increase susceptibility of peripheral blood mononuclear cells to HIV infection [3]. In addition
deworming can result in increases in CD4+ cells and reduction in plasma HIV-1 RNA concen-
trations [4]. Derangements in the immune response associated with HIV-infection might also
be expected to alter susceptibility to, or complications from, filarial infection or other hel-
minths such as Strongyloides [5]. To date, there are few studies that have investigated LF and
HIV co-infection and to our knowledge, none have been on a large population scale. A cross-
sectional study of 907 adults undertaken in Tanga region of Tanzania reported increased circu-
lating filarial antigen (CFA) concentration in HIV-positive persons [6], although a further eval-
uation of this group of individuals did not support any association between HIV and
Wuchereria bancrofti infection [7]. Similarly, in urban southern India, no quantitative differ-
ence inW. bancrofti CFA levels by HIV status was found in a study of 432 HIV-positive and 99
HIV-negative patients [8].
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Malawi embarked on a programme of mass drug administration (MDA) for LF control and
elimination in 2009 [9]. Concerns that the programme may be less effective in areas of high
HIV and LF prevalence prompted this study in Karonga, a district in the northern region of Ma-
lawi which was known to be highly endemic for LF infection [10]. Karonga is bordered by Lake
Malawi to the east, the Songwe river to the north (which also forms the boundary with Tanza-
nia), and by the Nyika plateau and escarpment to the west and south. The population is rural
and dependent on subsistence agriculture including rice growing and fishing from the lake.
Two previous studies had been undertaken by co-authors in the district and both had serum
samples stored with approval for later testing. The first was the recruitment phase of a rando-
mised controlled clinical trial that investigated alternative schedules and dosing regimens of
ivermectin and albendazole use in MDA programmes (study 1). Findings from this clinical
trial are reported elsewhere [11]. The second study was nested within a comprehensive
population-based HIV survey which enabled a longitudinal assessment of CFA in a whole
adult population (study 2). In this paper we report the prevalence and relationship of LF and
HIV infections from these two studies.
Methods
Study 1 used samples and data collected as part of the screening phase of a clinical trial of the
effectiveness of increasing the dose and frequency of albendazole and ivermectin as antifilarial
agents for clearing LF microfilaraemia (clinical trials registration number NCT01213576) [11].
It was undertaken between January 2009 to March 2012 in the northern portion of Karonga
district along the Tanzanian border and Songwe river delta. Villages in this area had previously
been shown to have a high prevalence of filarial antigenaemia and chronic manifestations of LF
[10]. No mass treatment interventions had been undertaken in the area at the time the study
was started.
Enrolment to the clinical trial required individuals to have a microfilarial count of>80
microfilariae per ml of blood. Consequently a population-based screening process was under-
taken to identify suitable participants for enrolment in the therapeutic trial. The estimated total
adult population of the target villages was 36,643 [12]. Sensitization meetings were held with
community members, the Traditional Authority (TA) and all the village headmen and their
aides who are administratively responsible for the study area. At these meetings the aims and
procedures of the study were explained. Following verbal approval by the community leaders, a
team of field workers went house-to-house seeking written consent and recruiting individual
participants. All households in selected villages were visited in sequence before moving on to
the next village. This screening phase was planned to continue until 120 eligible individuals
with appropriate microfilarial levels were recruited into the trial. However, screening and re-
cruitment into this study was discontinued following the rollout of the albendazole/ivermectin
national MDA programme in the study area as further recruitment into the clinical trial be-
came impractical. At the end of the recruitment phase individuals from 16 villages were includ-
ed. For analysis purposes smaller villages were combined in a geographically appropriate way
to produce 10 village location categories with suitable numbers of participants.
Individuals were eligible if they provided written informed consent, were residents of the
area and aged between 18 and 55. At each home visit, the study was introduced and explained
to all members and individual participants were asked to provide written informed consent by
signing (or thumb printing if they were illiterate) the informed consent forms that were translat-
ed in the local language (Tumbuka). A questionnaire was administered to capture personal de-
tails. Eligible individuals were screened for CFA by the immunochromatographic (ICT) card
test and for HIV by trained counsellors following the national HIV rapid testing algorithm.
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CFA positive individuals were asked to provide a night blood sample between 22:00 and 02:00
hours when a 5ml sodium citrate sample was collected for microfilaria counting and later stored
in the project laboratory archive at -20°C. All individuals who were CFA positive but declined to
participate in the clinical trial or did not meet the eligibility criteria for the trial were offered
standard dose antifilarial therapy with albendazole and ivermectin. Individuals who were HIV
positive were referred for HIV treatment and care. Assessment of HIV clinical stage, CD4 count
and viral load were not performed on these individuals as a part of the study protocol.
Study 2 used samples and data from an annual whole adult population survey. Repeated
rounds of data and sample collection spanned the time periods before and after the introduc-
tion of MDA. It was undertaken in the Karonga Health and Demographic Surveillance Site
(KHDSS) and nested within a comprehensive population-based HIV sero-survey [13]. The
KHDSS area is mapped and divided into geographically defined clusters of 20–30 households
which are further aggregated into 21 geographically distinct reporting groups. The KHDSS was
established between August 2002 and August 2004 to serve as a sampling frame for on-going
epidemiological and clinical studies. Unlike study 1, data from study 2 included detailed socio-
demographic information allowing for inclusion of these factors in statistical analysis. Since its
establishment, the initial population of the KHDSS has been under continuous demographic
surveillance. In addition, between September 2007 and October 2011 four annual HIV serolog-
ical surveys have been conducted in all individuals aged 15 or more years using rapid point-of-
care HIV tests on finger-prick whole blood samples [14]. Community sensitisation meetings to
explain the aims and procedures of the study were held in each village and were followed by
house-to-house visits by counsellors to recruit participants. The counsellors were trained and
certified by Malawi Ministry of Health staff to perform HIV counselling and testing and refer-
ral using standard procedures [15]. Written informed consent was obtained as in study 1. In
addition, all consenting adults were asked to provide a 5ml blood sample for quality control
and storage for further laboratory analysis including for other diseases of importance in Kar-
onga district. Plasma samples from consenting participants were stored in the project laborato-
ry archive at -20°C. Samples from the first surveillance round, which took place between
September 2007 and October 2008, prior to MDA introduction, were included in our study.
Viral load, CD4 counts and clinical staging were not measured as a part of the survey.
Common laboratory methods for both studies
The ICT card test (Binax, Portland, ME) [16] was only used as the screening test for LF infection
in study 1. This is a portable rapid point-of-care test suitable for screening in non-laboratory
settings and was used in accordance with manufacturer’s instructions. Microfilaria counting
was done on ICT card test positive individuals in study 1 by the nucleopore membrane filtration
technique [17]. This involves filtering a measured volume of venous blood through a 5μM pore
size nucleopore filter. After filtration, the filter is removed, placed on a glass slide and mounted
on a light microscope for examination and counting of microfilariae. Filarial antigenaemia was
quantified in all plasma samples in both study 1 and study 2 by means of the Og4C3 antigen-
capture ELISA (TropBio, Australia) [18]. Samples were analysed in accordance with the manu-
facturer’s instructions and expressed as antigen units per ml of blood (Ag/ml) based on control
samples supplied with the ELISA kits. Samples with CFA concentration more than 128Ag/ml
were considered clear positives for CFA. Samples with CFA concentration of 32Ag/ml and
below were considered negatives. Samples with a titre between 32 and 128Ag/ml were consid-
ered indeterminate.
In both studies HIV testing used whole blood rapid diagnostic tests according to Malawian
national guidelines [15] with demonstrated high accuracy in community settings in Karonga
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[14]. The initial screening test was with Determine TMHIV-1/2 (Abbott Japan Co Ltd, Japan)
and confirmatory testing was done with UniGold TM HIV-1/2 (Trinity Biotech PLC, Ireland).
Samples with a non-reactive screening test were considered negative and those with a reactive
screening and confirmatory test were considered positive. Where the screening and confirma-
tory tests were discordant, a tie breaker using a third rapid test, (SD Bioline, Korea) was used.
Common data management and statistical methods for both studies
Study forms were checked, coded, double entered and verified using Microsoft Access software.
Statistical analysis was done in Stata 12 software (StataCorp, Texas, USA). Continuous vari-
ables were log transformed prior to analysis to achieve an approximate normal distribution.
Linear regression was used for crude and adjusted analyses with results expressed as geometric
mean ratios (GMR) and their 95% confidence intervals. The association of age, gender and
CFA status with HIV positivity was estimated using χ2 tests for crude analyses and a logistic re-
gression model for adjusted Odds Ratios (OR). In a risk factor analysis for CFA positivity, lo-
gistic regression was used to estimate crude and adjusted ORs. Variables were retained in the
model if significant associations were identified in the unadjusted estimates. Geographic identi-
fiers for groups of survey villages were also incorporated in the models to adjust for geographic
confounding as previous surveys had indicated heterogeneity of CFA prevalence across the re-
gion [19]. Rather than a binary variable, HIV was treated as a categorical variable in the model
with the HIV—negative group and two HIV-positive groups based on ART use at the time of
blood sampling. A sub-group analysis to investigate the effect of cotrimoxazole and duration of
ART use on CFA prevalence was performed on the HIV-positive group only. Logistic regres-
sion models were used to estimate odds ratios. Difference in CFA prevalence with increased
use of ART was investigated with a χ2 test for linear trend with odds ratios derived from a 2xn
table. Adjusted odds ratios were estimated with logistic regression.
Ethics
The National Health Sciences Research Committee of the Malawi Ministry of Health (protocol
numbers 495 and 419) and the Ethical Committee of the London School of Hygiene and Tropi-
cal Medicine (protocol numbers 5344 and 5081) gave ethical clearance for both studies 1 and 2.
Study participants in both studies were consented for storage and later testing of samples at the
time of enrolment. This covered testing for HIV and other diseases of local significance. The
National Health Sciences Research Committee (protocol number 908) and the Ethical Com-
mittee of the Liverpool School of Tropical Medicine (protocol number 11.77) approved the ad-
ditional analysis conducted on stored samples.
Results
The overall population of Karonga district during the study period was 272,789 [12] with the
KHDSS population accounting for 33,500. HIV prevalence in the KHDSS in the 2007–2008
survey year was measured at 7.4% but estimated to be 10.4% when adjusted for non-testing by
those who already knew they were HIV-positive [20]. At baseline 54.8% of those aged 15 years
or more reported previous HIV testing.
Study 1
From the estimated total of 36,643 adults of the target villages, 1,851 individuals were eligible
and consented to participate. Of these 1,851 individuals screened for LF antigen by the ICT
card test, 447 (24.2%) were CFA positive (Fig 1). A total of 1,656 individuals accepted HIV
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testing and 169 (10.2%) of these were HIV-positive. HIV-positive individuals tended to be
older (Table 1). CFA positivity was present in 43 (25.6%) of HIV-positive and 351 (23.6%) of
HIV-negative (crude OR 1.11, 95% CI 0.77–1.60) with an LF/HIV co-infection prevalence rate
of 2.6%. CFA positivity did not differ by HIV infection status (Table 1). There was heterogene-
ity in the prevalence of CFA by village location, median 24.4%, range 15.7–33.3% (Pearson χ2
22.7, p<0.01, 9 degrees of freedom). Data on the use of antiretroviral and cotrimoxazole was
incomplete in the context of this study.
Microfilaria counting was done in the 311 (69.6%) LF antigen positive individuals who were
eligible and gave consent for night blood sampling. The remainder either refused or left before
follow up. HIV prevalence in those lost to follow up was broadly similar to those sampled
(10.3% vs. 9.3% respectively, χ2 test p = 0.90). Microfilariae were present in 49.5% of the 311
sampled individuals. Microfilarial detection and levels did not differ by HIV infection status
(Fig 1 and Table 1).
Of 311 stored baseline night blood plasma samples, 290 (93.2%) were CFA positive using
the Og4C3 antigen-capture ELISA. CFA was positive in 26 (89.7%) of HIV-positive individu-
als, 231 (93.9%) of the HIV-negative individuals and 33 (97.1%) of HIV-unknown individuals
respectively (p = 0.47). The geometric mean CFA concentration levels by HIV status were 859
and 1660 for HIV-positive and HIV-negative respectively (GMR 0.85, 95% CI 0.49–1.50). CFA
and MF counts showed reasonable positive correlation (Pearson correlation coefficient
r = 0.56, p<0.01).
Fig 1. Study 1 flow chart detailing the breakdown of individuals by HIV status, circulating filarial antigen (CFA) status by immunochromatographic
card (ICT) test andmicrofilarial counts. *2 individual had an invalid ICT test. MF—microfilaria.
doi:10.1371/journal.pntd.0003825.g001
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Study 2
The total eligible population of 15 year olds and older in the KDHSS at the baseline survey was
11,756. From this group, 7,863 (66.9%) underwent HIV testing and consented to storage of
their blood sample. Of these, 1,875 (23.9%) individuals were CFA positive by the Og4C3
ELISA. HIV infection was identified in 411 (5.2%) participants. HIV-positive adults tended to
be older and more likely to be female (Table 2). CFA positivity was present in 86 (20.9%) of
HIV-positive and 1789 (24.0%) of HIV-negative (crude OR 0.84, 95% CI 0.66–1.07) with an
HIV/LF co-infection prevalence rate of 4.6%. In the female participants, CFA positivity was
present in 17.8% of the HIV-positive and 19.8% of the HIV-negative (OR 0.88, 95% CI 0.64–
1.21) and in the male participants, 26.8% of the HIV-positive and 29.4% of the HIV-negative
(OR 0.88, 95% CI 0.60–1.28) respectively. Geometric mean CFA concentration was lower in
the HIV-positive individuals by 25% although this association was weakened when adjusted
for age and sex (Table 2).
Several risk factors were associated with an increased prevalence of CFA (Table 3). These in-
cluded male gender, age between 30 and 39 and lower quality housing, whilst decreased CFA
prevalence was associated with higher levels of education (p<0.01, χ2 for linear trend) the
availability of piped tap water or the use of lake water and the use of antiretrovirals. Bed net
ownership was high, however ownership or the number of nets owned in the household was
Table 1. Baseline characteristics of Study 1 participants by HIV status.
A
Characteristic HIV-positive (n = 169) HIV-negative (n = 1487) OR (95% CI†) Adjusted OR (95% CI)#
Age group
18–29 years 43 (25.4%) 727 (48.9%) - -
30–39 years 68 (40.2%) 406 (27.3%) 2.83 (1.90–4.23) 2.83 (1.90–4.23)
40 years and above 58 (34.3%) 354 (23.8%) 2.77 (1.83–4.19) 2.69 (1.77–4.08)
Sex
Male 66 (39.0%) 618 (41.6%) - -
Female 103 (61.0%) 869 (58.4%) 1.11 (0.80–1.54) 1.14 (0.82–1.59)
CFA status
Negative 125 (74.4%) 1135 (76.4%) - -
Positive 43 (25.4%) 351 (23.6%) 1.11 (0.77–1.60) 1.13 (0.78–1.65)
MF status
Positive 17 (58.6%) 123 (50.0%) - -
Negative 12 (41.4%) 123 (50.0%) 0.71 (0.32–1.54) 0.81 (0.35–1.85)
B
Characteristic HIV-positive HIV-negative GMR (95% CI) Adjusted GMR (95% CI)#
CFA GMC Ag/ml (95% CI) 859 (231–3193) 1660 (1198–2302) 0.85 (0.49–1.50) 0.91 (0.55–1.51)
C
Characteristic HIV-positive HIV-negative P value
MF count, median (IQR), mf/ml 0 (0–22) 1 (0–93) 0.13
A) The association of age group, gender and circulating ﬁlarial antigen (CFA) with HIV positivity. Adjusted Odds Ratio (OR) derived from logistic
regression model. B) Geometric mean concentration (GMC) of CFA in those CFA positive. Geometric mean ratio (GMR) derived from linear regression
model. C) Microﬁlaria (MF) count in those CFA positive expressed as median and interquartile range, difference assessed by rank sum testing owing to
the skewed nature of data.
†CI—conﬁdence interval;
# adjusted for age, sex and village location
doi:10.1371/journal.pntd.0003825.t001
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not associated with CFA prevalence. Individuals were found in all 21 reporting groups, with a
median of 314 participants (range 129–820). There was considerable heterogeneity in the prev-
alence of CFA by reporting group, median 23.2% range 5.7–37.2% (Pearson χ2 354.7, p<0.01,
20 degrees of freedom).
Of the 411 HIV-positive adults, 142 (34.5%) were taking antiretroviral therapy (ART) and
117 (28.5%) were using cotrimoxazole prophylaxis (CTX) with only 4 of the 117 taking CTX
without ART at the time of sampling. In 6 of the 411 individuals, information on ART and/or
CTX use at the time of sampling was unavailable. ART consisted of Lamivudine, Stavudine and
Nevirapine (Triomune-30) in 94% of cases with Zidovudine or Efavirenz substitutions in the
remainder. No protease inhibitors were in use. In the HIV-positive group, ART use was associ-
ated with a lower prevalence of CFA when compared to those not on ART [12.7% vs. 25.3%
(OR 0.43, 95% CI 0.24–0.76)]. Similarly, CTX use was associated with lower CFA prevalence
[12.8% vs. 24.1% (OR 0.46, 95% CI 0.25–0.85)]. In a multivariable model incorporating ART
and CTX use along with age, sex and geographical location, the adjusted odds ratio for ART
use was 0.47 (95% CI 0.17–1.31) and for CTX use 0.92 (95% CI 0.31–2.71). When the ART
treated group were further sub-divided by year since treatment started, there was a significant
trend to decreased prevalence of CFA with increasing time on treatment; 25.3% no treatment
(n = 265), 15.2% year 1 treatment (n = 59), 13.6% year 2 treatment (n = 44), 10.0% year 3 treat-
ment (n = 30) and 0% year 4 treatment (n = 9), (p<0.01 χ2 for linear trend). This relationship
persisted after adjustment for age, gender and reporting group. In the HIV-positive individuals
with detectable CFA, the geometric mean concentration of CFA was not significantly different
between those off and on ART, 647 vs. 512 Ag/ml respectively, GMR 1.27, 95% CI 0.76–2.08
(Fig 2), nor did the GMC differ by ART duration category 647, 392, 762, 516 & 0 Ag/ml for no
treatment, year 1, 2, 3 & 4 of treatment respectively.
Table 2. Baseline characteristics of study 2 participants by HIV status.
A
Characteristic HIV-positive (n = 411)# HIV-negative (n = 7452)# OR (95% CI†) Adjusted OR (95% CI)*
Age group
15–29 years 77 (18.7%) 3793 (50.9%) - -
30–39 years 159 (38.7%) 1480 (19.9%) 5.29 (4.00–6.99) 5.35 (4.04–7.07)
40 years and above 175 (42.6%) 2179 (29.2%) 3.96 (3.01–5.20) 4.02 (3.06–5.29)
Sex
Female 269 (65.5%) 4201 (56.4%) - -
Male 142 (34.5%) 3251 (43.6%) 0.68 (0.55–0.84) 0.72 (0.58–0.89)
CFA status
Negative 325 (79.1%) 5663 (75.9%) - -
Positive 86 (20.9%) 1789 (24.0%) 0.84 (0.66–1.07) 0.86 (0.67–1.10)
B
Characteristic HIV-positive HIV-negative GMR (95% CI) Adjusted GMR (95% CI) *
CFA GMC, Ag/ml (95% CI) 630 (511–778) 839 (799–882) 0.75 (0.60–0.94) 0.62 (0.38–1.02)
A) The association of age group, gender and circulating ﬁlarial antigen (CFA) with HIV positivity. Adjusted Odds Ratio (OR) derived from logistic
regression model. B) Geometric mean concentration (GMC) of CFA in those CFA positive, Geometric Mean Ratio (GMR) derived from linear
regression model.
# 2 HIV-positive and 26 HIV-negative with incomplete data;
†CI—conﬁdence interval;
* Adjusted for age, sex, and reporting group
doi:10.1371/journal.pntd.0003825.t002
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Table 3. The association of circulating filarial antigenaemia (CFA) prevalence with HIV and antiretroviral therapy (ART) status andmajor potential
confounding socio-demographic characteristics in the 7,863 study 2 participants.
Characteristic N (%) CFA prevalence (%) OR (95% CI#) aOR (95% CI)
HIV and ART status
HIV-negative 7452 (94.8) 1789 (24.0) Ref* Ref
HIV-positive—no ART 265 (3.4) 67 (25.3) 1.07 (0.81–1.42) 1.20 (0.90–1.62)
HIV-positive—ART 142 (1.8) 18 (12.7) 0.46 (0.28–0.76) 0.50 (0.30–0.84)
Gender
Male 3392 (43.1) 995 (29.3) 1.69 (1.52–1.88) 1.77 (1.59–1.98)
Female 4470 (56.9) 880 (19.7) Ref Ref
Age group
Age 15–29 years 3870 (49.2) 896 (23.2) Ref Ref
Age 30–39 years 1639 (20.9) 440 (26.7) 1.22 (1.07–1.39) 1.24 (1.08–1.43)
Age 40 years and above 2354 (29.9) 539 (22.9) 0.99 (0.87–1.11) 0.95 (0.84–1.09)
Mosquito net ownership
0 197 (2.5) 46 (23.4) Ref -
1 945 (12.0) 254 (26.9) 1.21 (0.84–1.73) -
2 1817 (23.1) 461 (25.4) 1.12 (0.79–1.58) -
3 1835 (23.3) 430 (23.4) 1.00 (0.71–1.42) -
4 2854 (36.3) 640 (22.4) 0.95 (0.67–1.34) -
unknown 215 (2.7) - - -
Educational achievement
Nil 277 (3.6) 83 (30.0) Ref Ref
Primary 5493 (71.3) 1379 (25.1) 0.78(0.60–1.02) 0.71 (0.54–0.93)
Secondary 1886 (24.5) 377 (20.0) 0.58 (0.44–0.77) 0.55 (0.41–0.75)
Tertiary 45 (0.6) 8 (17.8) 0.51 (0.23–1.13) 0.52 (0.22–1.19)
Unknown 2 (0.0) - -
Water supply
Bore hole 3755 (47.7) 1037 (27.6) Ref Ref
Tap to house 1082 (13.8) 105 (9.7) 0.28 (0.23–0.35) 0.30 (0.24–0.37)
Shared tap 835 (10.6) 127 (15.2) 0.47 (0.38–0.57) 0.48 (0.39–0.59)
Covered well 999 (12.7) 303 (30.3) 1.14 (0.98–1.33) 1.16 (0.99–1.35)
Open well 572 (7.3) 167 (29.2) 1.08 (0.89–1.31) 1.06 (0.87–1.30)
Lake 456 (5.8) 106 (23.3) 0.79 (0.63–1.00) 0.77 (0.61–0.97)
Unknown 11 (0.1) - - -
Housing type
Burnt brick 5750 (73.1) 1328 (23.1) Ref
Unburnt brick 678 (8.6) 169 (24.9) 1.11 (0.92–1.33) 1.00 (0.83–1.21)
Mud 1087 (13.8) 299 (27.5) 1.26 (1.09–1.46) 1.03 (0.88–1.20)
Grass/bamboo 167 (2.1) 49 (29.3) 1.38 (0.98–1.94) 1.14 (0.81–1.62)
Other 18 (0.2) 2 (11.1) 0.42 (0.10–1.81) 0.43 (0.10–1.91)
Unknown 163 (2.1) - - -
Crude and adjusted Odds Ratios (OR) derived from a logistic regression model. Data on reporting group are not shown in the table but adjusted models
include this as a potential confounder along with the other signiﬁcant variables in the crude analysis.
#CI—conﬁdence interval:
*Reference category
doi:10.1371/journal.pntd.0003825.t003
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Discussion
We present data from two separate studies undertaken in Karonga district, northern Malawi.
In both studies a high LF and HIV prevalence was measured with HIV co-infection rates of
2.6% and 4.6% among those who were CFA positive and 15 years and older. We found no evi-
dence that HIV is associated with an increased risk of LF infection. Initial findings from study
1, a clinical trial not powered to definitively test the impact of HIV on LF infection, revealed a
tendency to lower CFA and microfilarial density in the HIV-positive adults. Subsequent inves-
tigation of these parameters in the much larger population sample revealed a tendency to lower
CFA prevalence in the HIV-positive group, attributable to significantly lower CFA prevalence
in the ART treated sub-group, a finding that persisted following adjustment for key potential
confounders and showed a significant trend to lower CFA prevalence with duration of ART
use. There was no significant effect of CTX therapy, when analysed in a multivariable model.
CFA concentration was also persistently lower in the HIV-positive group although at a level of
uncertain clinical or public health significance.
Fig 2. Box plot of Circulating Filarial Antigen (CFA) concentration distribution (on logarithmic scale) by HIV and antiretroviral treatment (ART)
status for study 2 participants. The boxes show the median value and the interquartile range. The whiskers include all values within 1.5 times the
interquartile range with outliers shown as points. Comparison of CFA concentrations by group HIV- vs. HIV +/ART- (p = 0.22): HIV- vs. HIV+/ART+ (p = 0.05):
HIV+/ART- vs. HIV+/ART+ (p = 0.28), derived from a linear regression model adjusted for age, gender and reporting group.
doi:10.1371/journal.pntd.0003825.g002
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Previous studies have reported divergent findings with some showing an association be-
tween LF and HIV infections but these have tended to be small samples and in selected popula-
tions [6–8]. In contrast to these studies, our second study had a larger sample taken from a
whole population survey, including a high proportion of the at-risk population in an area with
high prevalence rates of LF and HIV. The findings in relation to ART use are novel and we are
unaware of other studies that have investigated this association. Individuals receiving ART
may represent a select group of the HIV-positive population who have better health seeking be-
haviour, may be more educated, live in better accommodation and/or may live in close proxim-
ity to health providers. However, as this work was undertaken in the context of a demographic
survey we were able to investigate these potential confounders by adjusting for reported educa-
tional status, housing quality, access to clean water and geographic location. The finding of
ART associated with a lower CFA prevalence appears robust.
An explanation for these findings remains less clear and merits further work. Residual con-
founding or an unrecognised selection bias remains possible, but seems unlikely given the high-
ly significant lower CFA prevalence with duration of ART therapy. The crude association of
CTX with lower CFA prevalence seems adequately explained by concomitant use of ART, and
there is no evidence to support either sulphonamides or trimethoprim, the components of
CTX, as effective antifilarial agents. If LF infection adversely impacts on the success of ART
therapy, then over time the prevalence of CFA positivity in this group will reduce as the LF/
HIV co-infected die. There is no evidence from the Malawi national HIV programme that out-
comes from ART treatment are worse in regions of the country endemic for LF compared to
those with low LF prevalence. Helminth infections have been linked to increased viral load in
non-ART treated individuals [21] but not to evidence of faster HIV progression [22]. Similarly,
LF infection had no significant effect on HIV disease progression in a study ofW. bancrofti
and HIV coinfections in south India [23]. Altered diagnostic accuracy of the Og4C3 ELISA in
the presence of ART has not been reported. ART has been rarely linked to false negative HIV
results in children and adults but this is more likely to be due to low levels of virus and/or anti-
body than a direct inhibitory effect. The reduction in CFA prevalence by ART treatment dura-
tion and the antigen capture nature of the Og4C3 ELISA would be difficult to explain by ART
inhibition of the assay. Immune reconstitution as a result of ART does not adequately explain
our finding either as there is a similar prevalence of CFA in the HIV-negative and the HIV-
positive untreated. There is no precedent for immune recovery following ART leaving the im-
mune system in a more competent state than an HIV-negative person. ART treatment is an im-
precise proxy marker of duration of HIV infection. If the natural history of LF in the HIV-
positive is a steady fall in antigenaemia could this explain the association? We do not have ac-
curate seroconversion dates for the majority of this population so are not able to fully consider
this possibility. However with ART use the “natural history” of HIV is dramatically altered and
it might be expected that any tendency to lower antigenaemia with time would also be altered
and this would be inconsistent with our findings. The most plausible explanation for this find-
ing is a direct filaricidal activity of the major ART agents. We are unaware of any data on the
effect of Lamivudine, Stavudine or Nevirapine on helminths. Further evaluation of these mole-
cules as antihelminthics would be appropriate.
Of the other factors associated with CFA positivity all have been reported previously, pro-
viding reassurance that the epidemiology of LF disease in Karonga is not unique and results are
generalizable to other similar regions. One surprise was the lack of association with bed net
ownership. However most households possessed bed nets limiting the power of any compari-
son, and during this survey we did not specifically ask about usage, or condition of the nets,
thus limiting the value of this finding. More detailed evaluation of this will be needed in
future work.
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Both of our studies had some degree of selection bias, but it is unlikely that this has funda-
mentally altered our findings. In study 1, we targeted villages known historically to have a high
prevalence of LF infection. If participation by HIV-positive individuals was reduced because of
perceived stigma associated with an HIV test, we may have had reduced power to identify an
association between LF and HIV. However, a similar finding in the much larger study 2 pro-
vides consistency. In study 2, we know HIV-positive adults were under-represented. Adults
who knew their status from earlier HIV testing studies or through routine service provision in
the district, declined participation [20]. However it is difficult to see a mechanism whereby LF
co-infection would disproportionately lead to non-participation by HIV-positive adults and in
particular ART treated HIV-positive adults thereby obscuring the true association.
More females than males were included in both studies. This may represent the easier access
to females at the time of recruitment since females are more likely to be at home. Although we
know men are more likely to be infected with LF in this population, we do not think this
under-representation has meaningfully affected the LF/HIV association. Sub-group analyses
showed similar odds ratios for the LF/HIV association by gender in study 2 suggesting no
major effect modification.
The measurement of our exposure (HIV) and outcome endpoints (LF status) were based on
accurate and well described tests and we do not believe these have introduced significant bias
into the study. We used different tests for assessment of circulating filarial antigen in the two
studies with different sensitivities and specificities, the ICT card test with sensitivity and speci-
ficity reportedly close to 100% and the Og4C3 ELISA test with 100% sensitivity and specificity
of at least 94% [24–26]. There was some disparity between these two tests identified in study 1.
This is consistent with previous studies that have reported overall agreement between the ICT
and Og3C4 tests but different sensitivities and specificities [24,25]. In study 2, we were not able
to assess MF counts due to the use of a stored sample collection. Whilst we cannot categorically
rule out an association between MF density and HIV, data from study 1 showed a positive cor-
relation between CFA levels and MF density. Previous studies have also shown a positive corre-
lation between CFA levels and MF density [26,27]. This implies that the CFA relationship will
broadly apply to MF counts.
In summary, we did not demonstrate a significant detrimental association between LF and
HIV in these studies that will have a negative impact on plans to eliminate lymphatic filariasis.
However ART treated adults had significantly lower CFA prevalence, a finding that merits fur-
ther careful evaluation to exclude an adverse impact of LF on HIV, or the potential of antiretro-
virals as molecules with antihelminthic properties.
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